drugset / Trial / NCT00650637

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

NCT00650637

Phase 3 Terminated 17 enrolled Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study was to determine the efficacy and safety of calcium carbonate for the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated diarrhea.

Timeline

Start
2003-01
Primary completion
2003-08
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium carbonate Other / unclassified 500 mg Oral
Background Lamivudine Other / unclassified 150 mg
Background Loperamide Small molecule 2 mg Oral
Background Nelfinavir Other / unclassified 1250 mg
Background Stavudine Other / unclassified 40 mg
Background Zidovudine Small molecule 300 mg

Indications